Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders - PubMed

3 days ago

GIP (Glucose-dependent insulinotropic polypeptide) is gaining renewed research interest for its therapeutic potential in metabolic and neurodegenerative disorders.
GIP has pleiotropic actions, including stimulating glucose-dependent insulin secretion and glucagon release during hyperglycemia, which may enhance insulin secretion via intra-islet α-β cell communication.
Beyond pancreatic effects, GIP promotes lipid storage in adipose tissue, reduces ectopic fat deposition, modulates bone remodeling, influences cardiovascular lipid metabolism, and exhibits neuroprotective properties.
GIP-based therapies show promise in improving glycemic control, reducing obesity-related inflammation, and enhancing insulin sensitivity.
GIP works synergistically with GLP-1, as demonstrated by the dual receptor agonist Tirzepatide, which outperformed semaglutide in clinical trials for reducing glycated hemoglobin and body weight.
GIP and its analogs may also help ameliorate pathology and cognitive deficits in neurodegenerative diseases like Alzheimer's.
Key research gaps include understanding GIP's tissue-specific signaling and optimizing its role in multi-agonist therapies for metabolic and neurodegenerative diseases.

Hasty Briefsbeta